ADAnthony J. DiMarino

Anthony J. DiMarino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony J. DiMarino has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies

    by Fabian A. Mendoza, Anthony DiMarino, Sidney Cohen, Christopher Adkins, Shady Abdelbaki, Satish Rattan, Christopher Cao, Susie Denuna-Rivera, Sergio A. Jimenez

    Oropharyngeal and esophageal dysmotility can cause serious clinical complications such as aspiration pneumonia, cachexia, and sarcopenia, with a resulting increase in mortality and disability. The current standard of care for the treatment of SSc-associated swallowing dysfunction is mainly supportive, although severe cases are usually refractory to conventional management. Recent studies have shown that the abnormal production of functional autoantibodies such as anti-cholinergic muscarinic receptor III antibodies may participate in the pathogenesis of SSc-associated gastrointestinal dysmotility and may provide a novel target for therapeutic intervention. We describe two patients with severe and rapid onset of SSc-associated severe swallowing dysfunction and esophageal dysmotility who had failed standard of care therapy, requiring complete enteral and parenteral nutrition. Both patients were positive for the presence of circulating antimuscarinic III receptor antibodies. They were treated with IVIG at a dose of 2 g/Kg/month divided in two consecutive days, for six months. Following IVIG therapy, both patients markedly improved their symptoms as shown by a reduction in their UCLA2.0 score, and achieved an improvement of esophageal motility documented radiologically. Both patients resumed oral feeding and had their feeding tubes removed within the treatment period. None of the patients developed severe adverse events attributable to IVIG, except for low-grade fever during IVIG infusion in one of the cases. These results provide support for the role of functional autoantibodies in the development of SSc-associated gastrointestinal dysfunction.


  • Open Access

    Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure

    by Joseph Yoo, Hie-Won Hann, Robert Coben, Mitchell Conn, Anthony J. DiMarino

    Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence, epidemiology, and hepatocarcinogenesis have been elucidated. Globally, hepatitis B virus (HBV) is still responsible for the majority of hepatocellular carcinoma (HCC). HCC is the sixth-most common cancer in the world and the second-most common cancer death. The ultimate goal of treating HBV infection is the prevention of HCC. Fortunately, anti-HBV treatment with nucleos(t)ide analogues (NAs), which began with lamivudine in 1998, has resulted in remarkable improvements in the survival of patients with chronic hepatitis B and a reduced incidence of HCC. These results were documented with lamivudine, entecavir, and tenofovir. Nonetheless, as the duration of antiviral treatment increases, the risk for HCC still remains despite undetectable HBV DNA in serum, as reported by different investigators with observation up to 4–5 years. In our own experience, we are witnessing the development of HCC in patients who have received antiviral treatment. Some have enjoyed negative serum HBV DNA for over 12 years before developing HCC. Current treatment with NAs can effectively suppress the replication of the virus but cannot eradicate the covalently closed circular DNA (cccDNA) that is within the nucleus of hepatocytes. There still remains a great need for a cure for HBV. Fortunately, several compounds have been identified that have the potential to eradicate HBV, and there are ongoing clinical trials in progress in their early stages.


  • Su1140 Boerhaave's Syndrome as a First Presentation of Eosinophilic Esophagitis

    by Whitney E. Jackson, Vaibhav Mehendiratta, Juan P. Palazzo, Anthony J. DiMarino, Daniel M. Quirk, Sidney Cohen

  • Polysomnographic Diagnosed Sleep Disorders Are Associated With an Increased Incidence of Asymptomatic Nocturnal Acid Reflux

    by Christine Herdman, Dina Halegoua-De Marzio, Paurush Shah, Susie Denuna-Rivera, Karl Doghramji, Sidney Cohen, Anthony J. DiMarino

  • S1244 Immunoglobulins (IgGs) from Systemic Sclerosis (SSC) Patients Attenuate M3 Muscarinic Receptor Activation in Rat Internal Anal Sphincter (IAS) Smooth Muscle Cells (SMC)

    by Jagmohan Singh, Vaibhav Mehendiratta, Francesco Del Galdo, Sergio A. Jimenez, Sidney Cohen, Anthony J. DiMarino, Satish C. Rattan

  • Open Access

    A retrospective analysis of medical or surgical therapy in young patients with diverticulitis

    by A. S. Greenberg, R. Gal, R. M. Coben, S. Cohen, A. J. Dimarino

    Background : Acute diverticulitis is increasingly being recognized in younger patients, but its management remains controversial. Aim : To compare long‐term outcomes of young patients treated with surgery vs. medical therapy for their first episode of diverticulitis. Methods : A retrospective chart analysis at a university and an affiliated community hospital between 1991 and 2002 revealed 149 patients ≤40 years of age with confirmed diverticulitis. Forty‐nine patients (38 males, 11 females) were contacted at least 1 year after their first episode of diverticulitis. Outcomes were compared based on initial therapy – antibiotics or surgical resection. The groups were compared by outcomes, gender, age, white blood cell count, temperature and diet. Results : Three (15%) of 20 surgical patients (mean follow‐up 6.89 years), and 16 (55%) of 29 medical patients had a recurrence of diverticulitis (mean follow‐up 5.72 years; P = 0.01). The treatment groups did not differ in age, white blood cell count, or temperature. Conclusions : (i) Surgical treatment is effective initial therapy but disease may recur in a minority of patients; (ii) medical treatment is less effective initial therapy, with recurrence in half of the patients; (iii) initial presentation is not a strong predictor of disease recurrence.


  • Clinical relevance of esophageal and gastric pH measurements in patients with gastro-esophageal reflux disease (GERD)

    by Anthony J. DiMarino, Sidney Cohen

    Background: Gastro-esophageal reflux disease (GERD) is a highly prevalent disease caused by the exposure of the esophagus to refluxed gastric contents. Proton pump inhibitors (PPIs) are the mainstay of current treatment. At present, the assessment of the efficacy of different PPIs in the treatment of GERD employs two measures: esophageal and gastric pH monitoring. Esophageal pH monitoring is the most accurate method of detecting reflux episodes and, therefore, its role as a diagnostic modality is well accepted. Gastric pH monitoring, on the other hand, is an accurate measure of gastric acid pH, but its relevance to patients with GERD is questionable, since recordings correlate poorly with esophageal acid exposure. Objective: This paper reviews (based on a Medline literature search, 1980–2004) the clinical relevance of esophageal and gastric pH measurements in both the management of GERD and in the evaluation of the efficacy of PPI therapy. Findings and conclusions: Evidence presented suggests that the assessment of esophageal pH yields data of greater relevance to patients with GERD than does data from gastric pH. This largely arises from the fact that esophageal pH monitoring assesses the pH of the refluxate and the frequency of reflux episodes at the mucosal site affected by the disease. The use of esophageal pH monitoring is recommended in patients who fail to present with endoscopic evidence of esophagitis, those with extra-esophageal symptoms, those who have failed traditional anti-reflux therapies, and those who are potential candidates for anti-reflux surgery. In recent years, the technique has benefited from the development of a wireless pH probe, and there is also an increasing body of evidence supporting its use in combination with other emerging technologies, such as Bilitec monitoring and multichannel intraluminal impedance. Such an approach is anticipated to aid both the diagnosis of GERD and the characterization of gastro-esophageal reflux (GER) in these patients.